MiNK-215

MiNK-215 is an investigational, off-the-shelf cellular immunotherapy developed to overcome immune resistance mechanisms and promote a potent anti-cancer immune response. It is an IL-15 armored, fibroblast activation protein (FAP)-targeting chimeric antigen receptor invariant natural killer T (CAR-iNKT) cell therapy. MiNK-215 is engineered to express a CAR targeting FAP, which is prevalent in stromal cells within the tumor microenvironment, and incorporates soluble IL-15 to enhance cell persistence. Preclinical studies have shown that MiNK-215 can eradicate tumor cells and deplete FAP+ immune-suppressive cells while increasing infiltration and persistence of proinflammatory cytotoxic T cells. This approach has demonstrated efficacy in models resistant to immune checkpoint inhibitors, particularly in microsatellite stable colorectal cancer (MSS CRC) with liver metastases[1][2][3][5][6].